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Aims The aim of this study was to evaluate the safety and efﬁcacy of transcatheter closure for perimembranous ventricular
septal defect (pmVSD) and its long-term results. The most common congenital heart condition is pmVSD. Transcath-
eter closure of pmVSD is a recently described technique with limited results for mid- to long-term follow-up.
Methods
and results
Between June 2002 and June 2008, 848 patients with pmVSD were enrolled in our study and treated percutaneously
with pmVSD occluders. All patients were followed up until December 2008, an average of 37 months. According to
colour Doppler transthoracic echocardiography before the intervention and ventriculography, the average end-dias-
tolic pmVSD size was 5.1 and 5.4 mm, respectively. Placement of the device was successful in 832 patients (98.1%)
and the median device size was 8.6 mm. During follow-up, 103 adverse events (12.4%) were reported. Most adverse
events were categorized as minor and there were nine major adverse events (8.7%), including two complete atrio-
ventricular block requiring pacemaker implantation. Kaplan–Meier estimates showed .85% freedom from major or
minor adverse events during a maximal follow-up of 79 months.
Conclusions In experienced hands, transcatheter pmVSD closure can be performed safely and successfully with low morbidity and
mortality. Long-term prognostic results are favourable, and the transcatheter approach provides a less-invasive
alternative that may become the ﬁrst choice in selected pmVSD patients.
This trial is registered with ClinicalTrials.gov, number NCT00890799.
-----------------------------------------------------------------------------------------------------------------------------------------------------------
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Ventricularseptaldefect (VSD)isacommoncongenitalheartdefect
inbothchildrenandadults.
1PerimembranousVSD(pmVSD),which
involves the membranous septum and the adjacent portion of the
muscular septum, accounts for about 70% of cases. Standard treat-
ment for pmVSD is open surgery, which is widely performed with
minimal operative mortality but still carries risks, such as complete
atrioventricular block (cAVB), residual shunt, postpericardiotomy
syndrome, and wound infection, etc.
1 Since the ﬁrst report of trans-
catheter VSD closure in 1988,
2 this catheter-based approach for
VSD has been shown to be an alternative to surgical closure with
acceptable mortality and morbidity as well as encouraging
results.
3–10 However, until now, reports on this treatment for
pmVSD have been limited to small series with insufﬁcient
follow-up.
11–15 According to a review by Butera et al.
14, the total
number of percutaneous closures of pmVSD worldwide was 366,
and the average follow-up period did not exceed 1 year. Both
large-scale and long-term follow-up results for this technique are
rare.Thus,thisstudywasdesignedtoevaluatethesafetyandefﬁcacy
of transcatheter closure of pmVSD and to characterize patients’
long-term clinical outcomes.
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Patients
From June 2002 to June 2008, 848 patients with pmVSD were enrolled
for attempted transcatheter closure using the pmVSD occluders avail-
able at our centre. The study was registered with ClinicalTrials.gov,
number NCT00890799, was approved by the ethics committee of
Xijing Hospital, and was carried out in accordance with the Declara-
tion of Helsinki (1996) and all relevant Chinese laws.
The occluders
Two types of pmVSD occluders (pmVSD-O) were used in the study:
the Amplatzer pmVSD-O (AGA Medical, Golden Valley, MN, USA)
and the domestic Shanghai pmVSD-O (Shape Memory Alloy Ltd,
Shanghai, China). The Amplatzer pmVSD-O and delivery system
have been previously described in detail.
16,17 The Shanghai
pmVSD-O is a symmetrical double-disk device (Figure 1)
10,18 made
of 0.005 in. nitinol wire mesh and fabric inside. The diameter of both
discs is 4 mm larger than that of the waist. The thickness of the
waist of Shanghai pmVSD-O is 3 mm while that of Amplatzer
pmVSD-O is 2 mm. The Shanghai pmVSD-O was approved in 2003
by the State Food and Drug Administration, P.R. China (SFDA), and
received CE mark in 2008. Device sizes are available from 4 to
20 mm in 1 mm increments.
Peri-operative protocol
In all pmVSD patients, transcatheter closure was indicated for haemo-
dynamic, symptomatic, or other medical reasons (Table 1). All patients
were routinely screened by conventional two-dimensional and colour
Doppler transthoracic echocardiography (TTE) with a Sonos 5500
ultrasound system (Hewlett Packard, USA). The following inclusion cri-
teria were used in this study: (i) congenital pmVSD as shown by echo-
cardiography; (ii) body weight .10 kg and age .2 years; (iii) maximum
VSD diameter ,20 mm by TTE; (iv) defect located at the 9 to 11
o’clock positions of an analog clock in the short-axis parasternal
view by TTE; (v) a distance of .1 mm from the pmVSD to the
aortic valve; (vi) left-to-right shunt; and (vii) calculated pulmonary vas-
cular resistance ,8 Wood units. The exclusion criteria were as
follows: (i) defects associated with other cardiac lesions requiring a
surgical approach; (ii) body weight ,10 kg and age ,2 years;
Figure 1 (A) Lateral view of the Shanghai symmetrical perimembranous ventricular septal defect occluder; (B) front view of the Shanghai
symmetrical perimembranous ventricular septal defect occluder.
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Table 1 Baseline characteristics of the patients
underwent transcatheter procedure (median with
range)
Patients (n) 832
Sex (F/M) [n (%)] 406 (48.8%)/426 (51.2%)
Age (years) 9.0 (2–73)
Age groups [n (%)]
,10 years 439 (52.8%)
10–20 years 283 (34.0%)
.20 years 110 (13.2%)
Weight (kg) 30.5 (10–88)
Indications
Symptoms (frequent respiratory
infections, oedema, NYHA
functional class II or greater.)
337 (40.5%)
Haemodynamic changes (cardiomegaly
on chest X-ray, left atrial, or left
ventricular enlargement veriﬁed by
echocardiography)
462 (55.5%)
Asymptomatic with heart murmur 23 (2.8%)
Previous SBE 10 (1.2%)
Echocardiography
Subaortic rim (mm) 2.8 (1.0–17.0)
Subtricuspid rim (mm) 5.3 (2.0–21.0)
VSD size (mm) 5.1 (1.3–15.5)
Heart function (NYHA grade)
I 786 (94.5%)
II 34 (4.1%)
III 12 (1.4%)
IV 0
LVEDD (mean+SD, Z score) 1.9+1.6
LVEDD, left ventricular end-diastolic dimension; NYHA, New York Heart
Association; SBE, subacute bacterial endocarditis.
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vascular resistance .8 Wood units; (iv) severe aortic regurgitation; (v)
severe aortic valve prolapse; and (vi) right-to-left shunt. Before inter-
vention, an informed written consent was obtained from all patients
or their parents. Physical examination, a chest X-ray, standard
12-lead electrocardiogram (ECG), and TTE were routinely performed
in all patients.
Device implantation
The catheterization procedure was performed under basal anaesthesia
without tracheal intubation for patients ,10 years of age and under
local anaesthesia and conscious sedation for patients .10 years of
age. Heparin (100 IU/kg) and antibiotics were administered intrave-
nously during the procedure. Access was through the right femoral
vein and right femoral artery. Angiography in the left ventricle at a
558/208 left anterior oblique projection/cranial was used to proﬁle
the pmVSD. Location, size of the pmVSD, and its relationship with
the aortic valve were assessed. Each pmVSD was categorized by
shape as tubular, window-like, aneurysmal, or conical (Figure 2A–D).
The diameter of the pmVSD was measured at the largest diastolic
phase, and an occluder was selected based on this measurement.
The defect was then passed from the left ventricle by a 5 Fr partly
cut pigtail catheter or a right Judkins catheter. An arteriovenous
circuit was set up through a femoral vein approach on the same
side. A long sheath (6–12 Fr) was advanced to the left ventricle
through the arteriovenous circuit and positioned beneath the aortic
valve. Through the long sheath, the pmVSD occluder was deployed
under ﬂuoroscopic control and echocardiographic guidance. Angiogra-
phy in the left ventricle and ascending aorta was performed again to
verify complete occlusion and to identify any new-onset aortic valve
regurgitation (Figure 2E–H). After the intervention, patients were
transferred to the general wards. Continuous ECG monitoring was
used during the ﬁrst 24 h after the procedure. Aspirin (5 mg/kg
daily) was administered for 6 months in all patients.
Follow-up protocol
All patients were followed up until December 2008, and the median
follow-up period was 37 months. Clinical examination, Holter or elec-
trocardiographic monitoring, chest roentgenogram, and TTE were per-
formed at 1, 6, and 12 months after the procedure and yearly
thereafter. Adverse events were ascertained at each assessment on
the basis of clinical evaluation. Thrombi, valve regurgitation, and
residual shunts were looked for using TTE. Complications were pro-
spectively recorded and divided into major and minor adverse events.
Adverse events
Events were graded as major or minor adverse events. Major adverse
events included but were not limited to death during or after the pro-
cedure because of complications of the procedure, cAVB requiring
pacemaker implantation, thrombo-embolism, and new-onset valvular
regurgitation requiring surgical repair. Minor adverse events included
but were not limited to groin haematoma, blood loss requiring trans-
fusion, device embolization with transcatheter removal, any cardiac
arrhythmia that required medication, new or increased valvular regur-
gitation less than two grades, haemolysis requiring medication, fever
.38.58C, rash, and loss of peripheral pulse. These minor adverse
events required medical intervention but were not life threatening;
they had no long-term sequelae and did not require long-term therapy.
Figure 2 Classiﬁcation of perimembranous ventricular septal defect and ventriculography before the release of the occluders. (A) In the
tubular type, the shunt jet is long, and the diameter in the left and right sides of the septum is the same. (B) In the window-like type, the
shunt jet is scattered immediately after crossing the septum. (C) In the aneurysmal type, the shunt jet has an aneurysmal shape. (D) In the
conical type, the shunt jet is wide on the left side of the septum and narrow on the right side. (E) Ventriculography before the release of occlu-
ders in tubular perimembranous ventricular septal defect, same patient as in (A). (F) Ventriculography before the release of occluders in
window-like perimembranous ventricular septal defect, same patient as in (B). (G) Ventriculography before the release of occluders in aneur-
ysmal perimembranous ventricular septal defect, same patient as in (C). (H) Ventriculography before the release of occluders in conical peri-
membranous ventricular septal defect, same patient as in (D).
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All continuous variables are expressed as mean+standard deviation
(SD) or median with range as appropriate, and discrete variables are
presented as frequencies and/or percentages. We used SPSS 16.0 for
Windows (SPSS, Inc., Chicago, IL, USA) for the statistical analysis.
Analysis of categorical variables was performed with the x
2 test or
Fisher’s exact test. Freedom from major or minor adverse events
was assessed by the Kaplan–Meier product-limit method.
Results
Patients
Among all 848 patients in whom we attempted transcatheter
closure of pmVSD, 832 patients (98.1%) were successfully
treated by transcatheter intervention. There were 406 male and
426 female patients. According to colour Doppler TTE before
intervention, the average end-diastolic pmVSD size was 5.1 mm.
Demographic and diagnostic data are summarized in Table 1.
Procedural details
According to ventriculography, the pmVSDs were classiﬁed into
four categories as described by Qin:
10 tubular, window-like, aneur-
ysmal, and conical. Altogether, 729 Shanghai pmVSD-Os and 103
Amplatzer pmVSD-Os were implanted. The mean measured
pmVSD size on ventriculography was 5.4 mm (1.2–17.2 mm),
and the mean pmVSD-Os size was 8.6 mm. A total of 62 combined
procedures were performed simultaneously, including 24 atrial
septal defect (ASD) closures, 18 patent foramen ovale (PFO) clo-
sures, 15 patent ductus arteriosus (PDA) closures, 2 muscular VSD
closures, and 3 pulmonary valvuloplasties. Immediate closure was
seen in 447 (53.7%) patients and all residual shunts diminished 3
months after the intervention. In our study, ﬁve pmVSD patients
who failed with the symmetric domestic Shanghai pmVSD-O due
to aortic regurgitation were successfully closed using the Amplat-
zer device. The median hospital stay was 3.3 days (1–25 days) and
median time to return to normal activities was 13.6 days (5–98
days) (Table 2).
Adverse events and follow-up evaluation
The median follow-up was 37 months (6–78.7 months). A total of
103 adverse events (12.4%) were reported in patients who under-
went attempted VSD closure. In our group, a residual shunt was
considered to be present when colour Doppler ﬂow mapping
showed a left-to-right shunt across the interventricular septum.
It was experienced in 352 of all 729 patients using Shanghai
pmVSD-Os and 53 of 103 patients implanting Amplatzer
pmVSD-Os. Comparison of the residual shunt rate between the
two groups showed no statistical signiﬁcance (x
2 ¼ 0.363; P ¼
0.547).
Altogether, nine major adverse events were observed in this
study. One 19-year-old girl died 7 days after transcatheter
closure, using an 8 mm Amplatzer pmVSD-O, in hospital because
of concomitant cerebral haemorrhage demonstrated by computer
tomography. The speculated reason was congenital cerebral vascu-
lar malformation. Other major adverse events included two cAVBs
requiring pacemaker implantation, two cases of new-onset valvular
regurgitation requiring surgical repair or replacement, two device
embolizations requiring surgical removal, and one case of bacterial
endocarditis. Complete atrioventricular block occurred in a
2-year-old boy 4 h after placement of a 6 mm Amplatzer
pmVSD-O and also in a 2.5-year-old girl 7 days after placement
of a 7 mm Shanghai symmetric pmVSD-O device. Both patients
received permanent pacemaker implantation and showed no
signs of rhythm recovery. Two patients suffered
moderate-to-severe tricuspid valvular regurgitation (180 and 746
days after the procedure using the Amplatzer and Shanghai
pmVSD-O, respectively) and underwent open repair. In one
patient, the tricuspid valve was encroached upon by the occluder,
leading to severe tricuspid valve insufﬁciency (Figure 3). The device
was fully endothelialized and removed. Aortic valvular regurgita-
tion was found in a 13-year-old girl who received a Shanghai
pmVSD-O, which was followed up closely. The regurgitation
gradually increased, and the girl underwent aortic valve replace-
ment 2.5 years later. Device embolizations were seen in two
patients: one occurred instantly, with a 6 mm Amplatzer
pmVSD-O embolizing into the pulmonary artery after release,
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Table 2 Procedural data and devices used (median
with range)
Fluoroscopic time (min) 12.5 (4–149)
Procedure time (min) 41.2 (22–342)
Catheterization
VSD size in ventriculography (mm) 5.4 (1.2–17.2)
PA systolic pressure (mmHg) 28.2 (18–75)
PA mean pressure (mmHg) 17.6 (14–56)
PA diastolic pressure (mmHg) 15.3 (11–42)
Qp/Qs 2.1 (1.5–8.5)
Defect shape, as determined by ventriculography [n (%)]
Tubular 239 (28.7%)
Window-like 77 (9.3%)
Aneurysmal 155 (18.6%)
Infundibular 361 (43.4%)
Type of device used [n (%)]
Amplatzer pmVSD-O 103 (12.4%)
Shanghai pmVSD-O 729 (87.6%)
Mean size of the device used (mm) 8.6 (4–20)
Combined procedures (n)
ASD closure 24
PFO closure 18
PDA closure 15
Muscular VSD closure 2
Pulmonary valvuloplasty 3
Median hospital stay (days) 3.3 (1–25)
Time to return to normal activities (days) 13.6 (5–98)
VSD, ventricular septal defect; PA, pulmonary artery; Qp/Qs, pulmonary to
systemic ﬂow ratio; pmVSD-O, perimembranous ventricular septal defect
occluder; ASD, atrial septal defect; PFO,patent foramen ovale; PDA, patent ductus
arteriosus.
Transcatheter PmVSD closure: mid-term results 2241while the other was noted at the 3 month follow-up, with the
Shanghai pmVSD-O migrating just to the bifurcation of the iliac
artery. Both patients underwent open surgery and recovered
well. Another severe adverse event, thrombo-embolization of
the ophthalmic artery, was seen in a 6-year-old girl with insufﬁcient
aspirin therapy at 95 days after transcatheter VSD closure. Her
right eyesight remained poor even after active medication.
Altogether, there were ﬁve major adverse events in the Shanghai
pmVSD-O group (0.69%) and four major adverse events in the
Amplatzer pmVSD-O group (3.9%). Fisher’s exact test showed sig-
niﬁcant difference between the two devices (P ¼ 0.017).
Most adverse events (91.3%) were categorized as minor, includ-
ing 13 groin hematomas, 2 blood transfusions because of blood
loss, 2 device embolizations with successful transcatheter
removal, 56 different types of cardiac arrhythmia that required
medication, 7 new or increased valvular regurgitation less than
two grades, 5 instances of haemolysis requiring medication, and
9 other minor adverse events (Table 3). Kaplan–Meier estimates
for freedom from major or minor adverse events are described
in Figure 4.
Except for the adverse events mentioned above, there were no
deaths, cardiac perforations, incidents of infective endocarditis,
device embolizations or malpositions, thrombus formations, signiﬁ-
cant arrhythmias, late cAVBs, or other morbidities during a median
37 month follow-up period. All patients were in normal sinus
rhythm and had a normal P–R interval, and there was no evidence
of conduction disturbance on ECG.
Discussion
Perimembranous ventricular septal defect represents the most
common congenital cardiac malformation, accounting for almost
one-ﬁfth of all defects, and it is more frequent in Asian countries.
14
Our previous study and literature from other major centres
showed that both open surgery and the transcatheter
technique can achieve extraordinarily good results in closing a
pmVSD.
19–21 Meanwhile, transcatheter closure has the advantages
of reduced psychological impact, less pain, and discomfort due to
the procedure, shorter hospital stay, no need for admission to
an intensive care unit, faster time to normal activities.
1,8,14 Differ-
ent devices have been used to close pmVSD,
2,22–24 among
which the Amplatzer pmVSD occluder and similar devices have
been shown to cause few complications and yield good
results.
5,8,11,13,16,25 However, long-term follow-up results with
these devices in a sufﬁcient number of patients have been
lacking.
8,15 This study was designed to evaluate the safety and efﬁ-
cacy of transcatheter closure of pmVSD and its long-term clinical
outcomes.
Figure 3 Removal of the perimembranous ventricular septal defect occluder in a 13-year-old boy 746 days post-intervention due to mod-
erate tricuspid insufﬁciency. (A) The tricuspid valve was encroached upon by the occluder, leading to moderate tricuspid insufﬁciency; (B) The
Shanghai perimembranous ventricular septal defect occluder was explanted, and the perimembranous ventricular septal defect was repaired.
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Table 3 Adverse events
Events No.
Major adverse events 9
Death 1
cAVB that required pacemaker implantation 2
New-onset valvular regurgitation that required surgical
repair
3
Device embolization that required surgical removal 2
Thromb-oembolism 1
Minor adverse events 94
Haematoma of the groin 13
Blood transfusion because of blood loss 2
Device embolization with transcatheter removal 2
Junctional rhythm 32
cAVB recovered after medication 3
LBBB 6
RBBB 15
Newor increased valvular regurgitation less than two grades 7
Hemolysis required medication 5
Others (fever .38.58C, rash, loss of peripheral pulse.) 9
cAVB, complete atrioventricular block; LBBB, left bundle-branch block; RBBB,
right bundle-branch block.
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device closure of perimembranous
ventricular septal defect
We have presented data from 848 patients who underwent
attempted transcatheter device closure of pmVSDs with a
median of 37 months of follow-up. In this study, we considered
effectiveness in terms of procedural success, complications, hospi-
tal stay, and time to return to normal activities. The present study
demonstrates an excellent immediate outcome and follow-up
results of transcatheter pmVSD device closure using pmVSD
occluders. Most pmVSDs were effectively closed, as evidenced
by stable device position and signiﬁcantly decreased interventricu-
lar ﬂow by echocardiography at all post-implantation time points.
Adverse events
Complications of transcatheter pmVSD closure in our study were
rare and occurred early in the vast majority of patients. Among all
103 adverse events (12.1% of the study population), only 9 major
adverse events occurred, with 1 non-procedure-related death.
Most adverse events (92 of 103) took place in the early stage of
the procedure, and only 11 events were observed during the
follow-up period after discharge. This outcome is quite different
from previous reports.
8,12,15,26 In our cohort, the most common
complications associated with transcatheter pmVSD closure
were heart rhythm disturbances (58 of 103). Other common
adverse events included valvular regurgitation, device embolization,
haemolysis, haematoma, and fever. These adverse events were
generally manageable and did not outweigh the beneﬁts.
Many types of cardiac arrhythmia may take place during the
transcatheter procedure. In our 832 cases, the most frequent
arrhythmia was a junctional rhythm, which occurred in 32 patients
(3.9%). Bundle branch block and transient AVB occurred in only
2.9% of patients (24 of 832) who underwent device closure. Five
patients experienced cAVB, of whom two patients were implanted
with permanent pacemakers; the other three patients recovered to
normal rhythm after effective treatment with dexamethasone and
isoproterenol. cAVB has been reported to be the most signiﬁcant
complication in both the early phase and follow-up period, with an
incidence varying from 3.5 to 8.6%.
12,27,28 In our study, the cAVB
rate was 0.23%, and no permanent cAVBs were experienced by
Qin et al.
10 using domestic symmetric devices. One large series,
reported by Andersen et al.,
19 of 2079 open VSD repair patients
showed a comparable cAVB rate of ,1%. The underlying mechan-
ism may be related to the modiﬁcation of the domestic symmetric
devices by enlarging the thickness of the waist from 2 to 3 mm and
using softer nitinol wire mesh to braid the occluder. Nonetheless,
careful monitoring of the heart rhythm remains mandatory
throughout follow-up due to the severe impact of and the charac-
teristically late onset of cAVB.
Valvular regurgitation was another major consideration in trans-
catheter closure of pmVSD. Impingement of the occluder on the
valve leaﬂets may cause instant aortic or tricuspid regurgitation
by interfering with the chordae tendineae.
27,29 Thus, echocardio-
graphy (TTE) and angiography are crucial for conﬁrming correct
device deployment. Among the 16 failed cases in our study, 12
were attributed to new-onset moderate-to-severe aortic regurgi-
tation (2 due to the inability to pass the VSD, 1 cAVB during the
procedure, and another 1 failed with the largest occluder avail-
able). We also identiﬁed one case of delayed moderate aortic
regurgitation (occurring 90 days post-intervention) that required
surgical repair, as well as two instances of late moderate tricuspid
regurgitation (occurring at 180 and 746 days post-intervention)
during follow-up. The mechanism may be associated with impro-
per placement of the occluder on the tricuspid septal leaﬂets,
migration of the occluder, shape memory of nithinol wires, or
rupture of the chordae tendineae.
27,30
Technical consideration of transcatheter
perimembranous ventricular septal
defect closure
Perimembranous ventricular septal defect involves the entire
membranous septum and adjacent structures and may have many
variations. The aortic valve, tricuspid chordae tendineae, atrioven-
tricular node, conduction bundle are all closely related to the
pmVSD. Therefore, technical consideration of transcatheter
pmVSD closure may be more important than in other types of
congenital heart diseases.
First, the inclusion/exclusion criteria for transcatheter pmVSD
closure should be strict. Severe aortic valve prolapse, a large
VSD with pulmonary hypertension, abnormal tricuspid chordae
tendineae origination, small infants with low body weight should
be referred for open surgery and excluded from transcatheter
intervention. In our centre, more pmVSD patients (n ¼ 1798)
were referred directly for surgery after TTE screening during the
same study period. It is likely due to this strict screening that the
success rate of transcatheter pmVSD closure in our group
reached 98.1%.
Second, passing the guide-wire and catheter across the defect is
a crucial step in transcatheter pmVSD closure.
10 Different types of
guide catheters can be useful in passing through the pmVSD, such
as the AR-1, 3DRC, right Judkins, and partly cut pigtail catheter.
Once the guide-wire passes the defect and is captured in the pul-
monary artery or vena cava, caution should be exercised in exam-
ining the shape of the arteriovenous circuit. Only when the
creation of the arteriovenous loop is not met with any resistance
Figure 4 Kaplan–Meier estimates of outcomes (freedom from
major adverse events and mixed major and minor adverse
events). Dotted lines are the 95% conﬁdence interval levels.
Transcatheter PmVSD closure: mid-term results 2243and this loop is straight, without kinks on frontal image ﬂuoroscopy
can we proceed with the procedure; otherwise, the tricuspid
chordae tendineae may be twisted, and repeating the passing pro-
cedure should be mandatory. Before releasing the device, angiogra-
phy of the ascending aorta is recommended to determine whether
aortic valve insufﬁciency is present. If new-onset aortic valvular
regurgitation is identiﬁed, either asymmetric devices or abandon-
ment of the procedure should be considered to prevent severe
complications.
Third, device selection is another important technical consider-
ation. The Amplatzer pmVSD occluder is an asymmetric device,
whereas the Shanghai pmVSD-O is symmetrical. In our study,
most pmVSDs could be successfully closed with the domestic sym-
metrical double-disk device. In pmVSDs with a short subaortic rim
or when aortic valve insufﬁciency was seen on the aortogram
before the release of the device, an asymmetrical Amplatzer
pmVSD occluder was selected. In addition, over-sized devices
should be avoided to prevent the occurrence of cAVB.
Lastly, transoesophageal echocardiography (TEE) is the imaging
modality most frequently used to guide transcatheter pmVSD
closure according to previous studies.
6,8,13,14 In our group, TEE
was used in the early stages of the study period and was gradually
replaced by TTE. Although TEE provides clearer images and is
more accurate, it extends the procedural time and is more compli-
cated. We used TTE combined with angiography to guide trans-
catheter pmVSD closure in our study, which remarkably reduced
the whole procedural time.
Limitations
Although our study demonstrated signiﬁcant beneﬁts of transcath-
eter pmVSD closure, it nevertheless had some limitations. First,
this was a single-centre, non-randomized study, and the experi-
ences of one centre may not be universally representative.
Second, all operators in this study were very experienced, having
each performed .200 cases. We admit that only in very experi-
enced hands can these techniques be carried out safely and can
the complications be managed properly.
26 Third, more pmVSD
patients (1798) were referred for surgery directly after TTE
screening in our institute and were not considered due to the
strict inclusion/exclusion criteria; this may demonstrate the impor-
tance of patient selection in assuring the safety and effectiveness of
this transcatheter technique.
Conclusions
This study has proved that transcatheter device closure is an effec-
tive method in treating pmVSD patients with excellent results in
experienced hands. The success rate was high, and the long-term
follow-up result was favourable. Adverse events were rare and
were generally manageable. The transcatheter approach provides
a less-invasive alternative to open surgery and may become the
treatment of choice for selected patients with pmVSD.
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Non-infectious large vessel vasculitis of the aorta: diagnosis by
echocardiography and cardiac positron emission tomography–computed
tomography
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A 59-year-old male was referred to
the General Internal Medicine Clinic
for investigation of slowly deteriorat-
ing general condition of unknown
origin. He had a 4-month history of
general fatigue, weight loss, chills,
and night sweats. Large screening for
a tumour aetiology was negative and
laboratory investigations revealed an
inﬂammatory syndrome with an
erythrocyte sedimentation rate of
86 mm/h and C-reactive protein of
143 mg/L. Blood cultures and exten-
sive viral and bacterial serology inves-
tigations, including Syphilis, were
negative. Transthoracic and transoe-
sophageal echocardiography showed
a dilated aortic root with marked
thickening of aortic wall appearing as
a cuff-like circumferential mass
(10 mm, white arrows, Panels A–D).
There was no signiﬁcant valvular dysfunction and no image suspicious for valvular vegetation. The mass was inﬁltrating the interven-
tricular and interatrial septum (white asterisk, Panel C). Differential diagnosis included cardiac tumour, abscess or phlegmon, and
inﬂammatory disease. A cardiac positron emission tomography–computed tomography (PET–CT) was performed and disclosed
enhanced ﬂuor-18 ﬂuorodeoxyglucose (FDG) uptake in the wall of the aortic root, ascending aorta (Panel E, black and white
arrows, respectively), and, less pronounced, in the descending and abdominal aorta. Non-infectious large vessel vasculitis (probable
giant-cell arteritis) was suspected and immunosuppressive treatment with high doses of steroids was initiated. At early follow-up, there
was marked improvement of symptoms with normalization of inﬂammatory parameters. A control cardiac PET-CT 4 months later
showed nearly complete regression of the FDG uptake in the aortic wall (Panel F). This case emphasizes the complementary role
of echocardiography and PET-CT in the diagnosis of large vessel vasculitis.
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